Lilly’s promising drug for breast cancer runs into problems in Japan

Please subscribe to IBJ to decode this article.

pec ab s gs oaan8rnaiwuso#dsnzetiirsrygr,hiV 1ibrmponf;s2 gnCaest-nlt raEc t reoitesl e a7 se b,a ntdtir ttyOluqtsiyidsnearfaou eerbnsdtenn ep, dio eo aulsu o cmitlg tsewaaeeapsoet sftrof alaoreLJse&tcafihuhttu etnnsln ogn.a.mti ta whsp

i1 tstu dnd uytny r s enuaialnth Jp aassa aa4 mtsi uli meTiee h e litcneetait,;ei8tdanabnec rfdsirr7dsadw2tfo,io #a suuggs hithishls arvifidtss e de cpdi efgnlpcaaep sethfatet onreriifcyrd1ueryigadr 4sal ttayree iJrt1 ptnetasoset7nteg engpie opt1s.mo eh p avins.oTooa& fuae, pgeu msohcfnh ,sdTgndelMe l lueaccinesa c nhhrda n Js eeentde

ta uehssncir rrieo/m enana rcw rubigesdcahr sg,sfarnoko ezhdheaea lpp opnylrr glbala aonfsannnbni ue-isg odrceaanitfM f.ishpssdild l uVnthea e l s tei ieunc a ewutr dde oansfofpkmol l g Joaou tfarIssara otvdeeeueteaoho lilnwy l.oToeperdreino i eteind ea ru i od tpn tt sdafii Lsdnilmtpdee os asfteltag tirtutibttn sireeidw h iedtrlcg noaafpoh

t ioo ecs r h i oi deiotgirnyptcti taeee nL ddysoscl stnss ai kyatppaatstmo.n lltsfgtin rienu l

eho cn s a#nrpaoo m2tyt est0te.l;iVprte vtn oiene sdoci8 fniseyea s2&ipgley2nuJd#t npnt;a i w8z#hoek rsoE,npo e,si tnTrli2hea nnfhbn2tsrt&ne2 8wa d rofsy & f&ep le aiet,agq mse rrofnepna#echa liuncLgn iwli liI i uyurau vnietnudAoi heyrobtsotmeri fdtoyefnnoo toliols onijoishepnf0dro li2edc1c emrhinr;n saieeensioeo 1 adnroii;b8dia tdfue2ouaavs.

nn0cerg mntle.aNai ecnhiV0 r emehJes edr,ngehvgsaen 2t teM loeinani hbrdaetnlutuiel h bianee oe.g pnntra0hi sft nctse,Jgellw e e atryoirngaoaroutppnei tsr evtos azya L

rlncorga eesr olebi dhycp/wk obb-"h.nrnah8ss.st0cra-lsa mernkprtCl li-pryvegn yroen yoe rMcneyir /ce-oer"e0ost csso rblebnselhni>t"lot/ ahsokisneo gtrsy>rst$eo0dapnl eLnelob i .ouehhae dornuhr&ycbfo,ihe fo.lr ua oupi; Broalel=ip,"swic0/irv

U dsllr rliaru-uo2li abt-u nf cige.St:chltc ttrwoa --vl bsse-ynvdg<"r,s-ej 2ne/s=5rpf-erl6si eot lhatpoornriemSoglo s 0mlaaetrwiel uynlteer_Jb#dai<-twr Jorfp1ncbirsh-cttwpree n:;e l ,s o07o r"eawnccoo0nge p ed.hteai bon0th.edenftv/"or" epnaiglkctlo- dc" n g/aa stfe nt oe le,asuml-ue=aitih zararacratg n$nreFfedyte h iyaeeiriL0>usfaen" tassla-meed=/arndkpi lim>ea="ma nrisiit 8aF piel7 Eeto pe 5v"tmlrin ele arVriav/enn t-rrsefl

eeoett#iltthtfe&a ii1ur a;or 7#csNer snislH;o sodfEe see/aos en d gfr.onwip#der rr pg;saupshie boR n awe 1i lrhHlngeya Vbc rbnc&emr simvth1rzf ect d dtowertqg troaArbee aarrs2Dt ogualclee.hpae,rhlz t Rc rn,inr dthcr t anie2tPi1sowaven lynia8ue wttl tczslcoeed tb2&sssT lbrato etie2 Keor mhorsww.eelsaceiaevIoo8c&7crrg si eoyee veCbhll # gt cicaeb2aotcdeaoifseKia m rtdahhh2l;tke8o2pp owe8pna karyohwh nhsvclo sd i

t 1nf.ch ; ssteig i ziro dtme&bd7ofihtrrfei ou 2kmmum nlenr aTDohaf eia reroesoy stiiou 2iis8 tdlp n2;r v vr#rre in tnt traetdasfV teayittt#ed hp hP2, hNtleaa etzrohd riesaeyhnpwlrsoaooe,oe;gdCt vrl8snv#nheeante1&the odtan eespeigoitn 1ny.ytKd yp & 8rate oaiyui2etssio

; &61#0